Neurosteer EEG Brain Monitoring Platform Earns FDA Nod

Neurosteer Inc. has gained U.S. Food and Drug Administration (FDA) clearance for its Neurosteer single-channel EEG brain monitoring platform.
 
In the ICU, the unobtrusive multi-purpose system offers continuous brain monitoring to support critical interventions. In a doctor’s office, it can help detect pre-symptomatic cognitive decline, including Alzheimer’s, Parkinson’s, and dementia. In pharma drug trials, it can help to quickly and cost-effectively mass screen subjects who might be suffering neurodegenerative disorders.
 
Neurosteer uses an adhesive electrode strip connected to a pocket-sized sensor that wirelessly transmits EEG data to the cloud for advanced signal processing. It offers traditional EEG frequency bands and is also FDA-cleared for several novel “brain metrics” visual representations.
 
The system also includes a noninvasive assessment with auditory prompts that can aid in early detection of brain deterioration.
 
Dr. Amitai Bickel, Surgeon at Western Galilee Hospital, commented to the press, “After working with the Neurosteer EEG system for several years, I’ve realized what an advantage it is to have a compact, easy-to-apply EEG brain monitor that can be used for real-time continuous monitoring. Neurosteer’s innovative platform has the potential to revolutionize the standard of care in managing brain health.”
 
Dr. Nathan Intrator, founder and CEO of Neurosteer, said, “We are extremely pleased that the FDA has cleared our portable and affordable EEG system, and moreover, recognized the potential clinical value of our brain metrics visual representations. This is an important step in achieving our goal of making brain monitoring and assessment widely available to all populations.”